Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | ACACB | O00763 | 4/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11928910 | 0.92 | EPHX1 (0.35) | CTSLCTSSCYP3A4MAPK1ACACB | |
| SCHEMBL13183765 | 0.92 | EPHX1 (0.35) | CTSLCTSSCYP3A4MAPK1ACACB | |
| SCHEMBL13122196 | 0.88 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL18117337 | 0.88 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL888675 | 0.88 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL8923279 | 0.84 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL890192 | 0.84 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL12330853 | 0.84 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL13154796 | 0.84 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA | |
| SCHEMBL18117412 | 0.84 | CTSL (0.37) | CTSLCTSSMLNRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CTSL 312/4885CTSS 571/4885MLNR 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.